Verteporfin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Verteporfin
- Verteporfin: From Age-Related Macular Degeneration to Mitochondrial Oxidative Phosphorylation Disorder
Verteporfin: From Age-Related Macular Degeneration to Mitochondrial Oxidative Phosphorylation Disorder
One-Sentence Summary
Verteporfin is a photosensitizing agent developed for photodynamic therapy (PDT) of choroidal neovascularization in wet age-related macular degeneration. The TxGNN model predicts potential efficacy for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but this direction is currently supported by zero clinical trials and zero publications — it is a pure graph-based association with no known mechanistic pathway.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Choroidal neovascularization / wet age-related macular degeneration (photodynamic therapy) — inferred from drug class; not present in the structured original_indications field |
| Predicted New Indication | Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 99.49% (graph rank #5,563) |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured record. Based on known information, Verteporfin is a photosensitizer / YAP inhibitor: upon light activation it generates reactive oxygen species that occlude abnormal vasculature (its approved ophthalmic PDT use), and independent of light activation it is also known to inhibit the YAP/TAZ–TEAD transcriptional axis of the Hippo pathway.
For this specific predicted indication, however, the evidence pack’s own rationale is explicit that no known mechanistic pathway connects Verteporfin to nuclear-DNA-related mitochondrial oxidative phosphorylation disorders. Neither the vascular-occlusion (PDT) mechanism nor the YAP-inhibition mechanism has an established link to nuclear-DNA-encoded OXPHOS complex assembly or mitochondrial bioenergetics. The high TxGNN score therefore reflects a knowledge-graph pattern association rather than a biologically grounded hypothesis, and should be treated as a hypothesis-generation signal only, not as mechanistically supported repurposing evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This predicted indication has no supporting clinical trials or literature, and the mechanistic rationale explicitly notes the absence of any known pathway linking Verteporfin to nuclear-DNA-associated mitochondrial OXPHOS disorders. The evidence level (L5) reflects a model-prediction-only signal, which does not meet the threshold to advance beyond hypothesis stage (S0).
To proceed, the following is needed:
- Verteporfin’s detailed mechanism of action data (currently flagged as a blocking/high-severity data gap; DrugBank API query pending)
- TFDA/regulatory label warnings and contraindications (currently a blocking data gap for any safety pre-screening; requires SmPC/label retrieval)
- Preclinical or mechanistic studies directly testing Verteporfin’s effect on nuclear-DNA-encoded OXPHOS complex function or mitochondrial disease models
- Independent expert review of the TxGNN graph association before any further prioritization
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.